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Cardiovascular mechanisms activated by microinjection of
baclofen into NTS of conscious rats. Am J Physiol Heart Circ
Physiol 284: H987–H993, 2003. First published November
27, 2002; 10.1152/ajpheart.00447.2002.—The peripheral
mechanisms responsible for pressor response produced by
microinjections of baclofen (GABAB agonist) into the nucleus
tractus solitarii (NTS) of conscious rats were studied. Bilat-
eral microinjections of baclofen (10–1,000 pmol/100 nl) pro-
duced a dose-related increase in mean arterial pressure
(MAP) and heart rate. The maximal response was observed
after 15 min. Intravenous injection of prazosin decreased
MAP to control levels. Subsequent treatment with Manning
compound (vasopressin receptor antagonist; iv) produced an
additional decrease in MAP. In a different group of rats,
vasopressin antagonist was injected first and MAP was sig-
nificantly decreased; however, it remained elevated com-
pared with prebaclofen injection levels. Subsequent treat-
ment with prazosin abolished the baclofen-induced pressor
response. Reductions in baclofen-induced pressor response
with prazosin treatment were followed by a reflex tachycar-
dia in animals that received a 100 pmol/100 nl dose of
baclofen. The tachycardia was not observed with a dose of
1,000 pmol/100 nl. The pressor response induced by microin-
jection of baclofen into the NTS of conscious rats may be
produced by both increases in sympathetic tonus and vaso-
pressin release.
GABAB agonist; prazosin; blood pressure; vasopressin; car-
diovascular control; baroreflex
THE MAJORITY OF CARDIOVASCULAR and respiratory affer-
ents relay to the central nervous system (CNS) via the
vagus and glossopharyngeal nerves and terminate in
the nucleus tractus solitarii (NTS) (12, 17). The NTS is
a major site of reflex integration, and it is also richly
innervated from regions of the CNS concerned directly
or indirectly with cardiorespiratory control (17), chang-
ing both the activity of the sympathetic nervous system
(SNS) and vasopressin (VP) release (27).
The role of GABA in the NTS has been investigated
in the last decade. The baroreceptive region of the NTS
contains a high density of GABA-containing nerve ter-
minals (2, 11, 16, 20, 24, 25) and a high density of both
GABAA and GABAB receptors (4, 10, 25). Previous
studies (3, 9, 22, 29, 31) demonstrated that stimulation
of GABAB receptors in this region of the NTS elicits a
marked pressor response in anesthetized rats. In con-
scious rats, systemic administration of baclofen causes
a sustained hypertension and tachycardia (23).
Anatomic studies showed projections from the NTS
to neurons of the paraventricular nucleus of the hypo-
thalamus to and from the NTS to the spinal cord (6, 18,
32). Previous results showed an important participa-
tion of VP in the pressor response produced by micro-
injection of muscimol (GABAA agonist) and nipecotic
acid (inhibitor of GABA uptake) into the NTS of anes-
thetized rats (7). Moreover, extensive chemical or elec-
trolytic lesions of the NTS demonstrated that, in addi-
tion to VP, the SNS is involved in the pressor response
(1).
The mechanisms related to the hypertension ob-
served after baclofen injection into the NTS are not yet
clear. Several mechanisms can be considered for this
hypertension, the possibility of an increase in sympa-
thetic tonus or release of vasopressin, or both. In this
study we sought to determine the cardiovascular ef-
fects induced by bilateral microinjections of baclofen
into the NTS of conscious rats and the mechanisms
involved in these effects.
METHODS
Male Wistar rats (300–350 g) were used in the present
study. Rats were allowed free access to food and water. All
experimental protocols were approved by the Institutional
Ethical Committee.
Rats were anesthetized with pentobarbital sodium (40
mg/kg ip; Sigma, St. Louis, MO) and placed in a stereotaxic
apparatus (model 960; David Kopf, Tujunga, CA). Bilateral
guide cannulas were implanted in the direction of the NTS in
accordance with a previously described technique (8). In
brief, a small window was opened caudal to lambda, through
which a pair of 15-mm-long stainless steel guide cannulas (22
gauge) were introduced in a perpendicular way 14.5 mm
caudal to the bregma, 0.5 mm lateral to the midline, and 5.7
mm below the skull surface of the bregma. The bottom of the
guide cannulas was placed in the cerebellum 1.0 mm above
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the dorsal surface of the brain stem. Guide cannulas were
fixed to the skull with screws and methacrylate and then
closed with an occluder until the beginning of the experi-
ment. The needle (33 gauge) used for microinjection into the
NTS was 2.5 mm longer than the guide cannulas and was
connected with a polyethylene-10 (PE-10) tubing to a 1-l
syringe (Hamilton, Reno, NV). Five days after placement of
the NTS cannulas, rats were anesthetized with halothane
(Halocarbon), and PE-50 catheters (Clay Adams, Parsippany,
NJ) were introduced through the femoral artery and vein to
measure pulsatile arterial pressure (PAP) and heart rate
(HR) and for drug administration, respectively. Both cathe-
ters were tunneled subcutaneously and exteriorized through
the back of the neck. PAP and mean arterial pressure (MAP)
were determined with a pressure transducer (Statham
P23Db) connected to a low-level DC preamplifier in a poly-
graph (Grass model 7D). HR was derived from arterial pulse
wave by a cardiotachometer. Animals were permitted a 24-h
period to recover before the experiments.
First protocol. The dose-related effects of baclofen (10, 50,
100, or 1,000 pmol/100 nl; Sigma) on MAP and HR were
studied. In this protocol MAP and HR were measured in
awake rats immediately before and 15 min after microinjec-
tions into the NTS. Different groups of rats were used for
each dose. All NTS sites were previously characterized by
L-glutamate microinjection (50 mM).
Second protocol. MAP and HR were determined immedi-
ately before and 15 min after bilateral microinjections of the
GABAB receptor agonist baclofen (100 or 1,000 pmol/100 nl)
into the NTS. Fifteen minutes after baclofen, an 1-adrener-
gic antagonist (prazosin, 1 mg/kg iv) and a VP antagonist
{1--mercapto-,-cyclopentamethylene propionic acid 2-[0-
(methyl) tyrosine] arginine vasopressin; Manning compound,
10 g/kg iv} that were administrated with a 15-min time
interval between drugs. A control group of animals was
maintained to verify the effect of the vasopressin antagonist
on basal MAP and HR. Bilateral NTS sites were character-
ized by L-glutamate microinjection (50 mM). After that, ve-
hicle (saline 0.9%) was microinjected bilaterally into the
NTS, followed by intravenous injection of the VP antagonist
(10 g/kg).
Third protocol. MAP and HR were determined immedi-
ately before and 15 min after bilateral microinjections of the
GABAB receptor agonist baclofen (100 or 1,000 pmol/100 nl)
into the NTS. After 15 min, the VP antagonist (Manning
compound, 10 g/kg iv), followed by the 1-adrenergic antag-
onist (prazosin, 1 mg/kg iv), were administrated with a 15-
min time interval between drugs.
Immediately after the experiments, Evans blue (2%) was
microinjected into the same site as the microinjections as a
marker for histological analysis. Animals were then killed
with an overdose of pentobarbital sodium (200 mg/kg), and
10% buffered Formalin was introduced by intracardiac per-
fusion. Brains were removed and stored in buffered Formalin
for 2 days before 40-m serial coronal sections were cut and
stained by neutral red. Successful microinjection placements
into the NTS (Fig. 1) were confirmed for all animals included
in this study. In rats in which the microinjections of baclofen
were inappropriately placed into adjacent areas to the NTS,
no significant changes in arterial pressure and HR were
observed (data not shown).
Data were obtained by subtracting the peak of the re-
sponse to the treatment from the basal level. The dose-
Fig. 1. Photomicrography and schematic representation of a coronal
section of the brain stem showing typical bilateral microinjection
sites in the nucleus tractus solitarii (NTS). Arrows indicate center of
microinjections; DVN, dorsal motor nucleus of vagus; XII, hypoglos-
sal nucleus.
Fig. 2. Changes in mean arterial pressure (MAP) elicited by bilat-
eral microinjection of increasing doses of baclofen (10, 50, 100, and
1,000 pmol/100 nl; n  5, 7, 7, and 8, respectively) into the NTS of
conscious rats. The effect was dose dependent (P  0.05). Values
were measured 15 min after microinjections.
Table 1. Dose response to bilateral microinjections
of baclofen into NTS
Doses of Baclofen,
pmol/100 nl MAP, mmHg
HR,
beats/min
0 12 	84
10 95* 41
50 183* 71
100 374* 	52
1,000 663* 845*
Values are means  SE maximum change () after injection. A
different group of animals was used for each dose (saline, n  6; 10
pmol, n  5; 50 pmol, n  7; 100 pmol, n  7; and 1,000 pmol,
n  8), which received bilateral microinjections of baclofen in a
volume of 100 nl of saline solution. *Significantly different compared
with control (P  0.05).
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Fig. 3. Effects of bilateral microinjection of 100
pmol/100 nl (A) and 1,000 pmol/100 nl (B) baclofen
into the NTS, followed by intravenous injection of
prazosin (1 mg/kg) and vasopressin antagonist (AVP
ant; Manning compound, 10 g/kg) on pulsatile ar-
terial pressure (PAP), MAP, and heart rate [HR,
beats/min (bpm)]. Interval of time between treat-
ments was 15 min.
Fig. 4. Effects of bilateral microinjec-
tion of 100 pmol/100 nl (A; n  6) and
1,000 pmol/100 nl (B; n  6) baclofen
into the NTS and intravenous injection
of prazosin (1 mg/kg) and vasopressin
antagonist (Manning compound, 10 g/
kg) on MAP and HR. *Different com-
pared with control (P  0.05); †differ-
ent from baclofen (P  0.05).
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response curve is presented as change of the mean  SE.
Other results are shown as absolute means  SE.
Results were analyzed by one-way analysis of variance
(first protocol) and by one-way analysis of variance with
repeated measures (second and third protocols). Post hoc
determination of differences was established by Newman-
Keuls correction for multiple comparisons, with P  0.05
being regarded as significant.
RESULTS
Effects of bilateral microinjections of baclofen into
NTS on MAP and HR. Bilateral microinjection of ba-
clofen into the NTS of conscious rats (10, 50, or 100
pmol/100 nl) produced dose-dependent increases in
MAP [9  5 (n  5), 18  3 (n  7), and 37  4 (n  7)
mmHg, respectively; P  0.05, Fig. 2] but had no effect
in HR (Table 1). Bilateral microinjection of 1,000 pmol/
100 nl baclofen increased both MAP (66  3 mmHg,
n  8; P  0.05) and HR (84  5 beats/min, n  8; P 
0.05) (Table 1; Fig. 2). The pressor response induced by
these treatments was sustained for at least 1 h, except
in the group microinjected with 1,000 pmol/100 nl
baclofen, which animals developed respiratory depres-
sion after 30 min.
Effects of administration of prazosin and Manning
compound on MAP and HR after bilateral microinjec-
tions of baclofen into NTS of conscious rats. Bilateral
microinjection of baclofen (100 pmol/100 nl) increased
MAP from 103  6 to 152  6 mmHg and HR from
345  17 to 388  13 beats/min (n  6; P  0.05).
Fifteen minutes after NTS microinjection, intravenous
injection of the 1-adrenergic receptor antagonist pra-
zosin (1 mg/kg) lowered MAP from 152  6 to 91  6
mmHg and increased HR to 483  3 beats/min (P 
0.05). Fifteen minutes after prazosin treatment, injec-
tion of the vasopressin receptor antagonist Manning
compound (10 g/kg iv) further decreased MAP from
91  6 to 83  8 mmHg (n  6; P  0.05). However, no
additional change was observed in HR (see Fig. 4A).
Figure 3A shows a representative tracing from an
animal of this group.
The same protocol was performed in a second group
of animals (n  6) that were bilaterally microinjected
with 1,000 pmol/100 nl baclofen in the NTS. In these
rats, MAP increased from 111  3 to 171  3 mmHg
and HR increased from 348  8 to 445  9 beats/min
(P 0.05). After intravenous microinjection of prazosin
MAP decreased from 171  3 to 119  2 mmHg (P 
0.05), and a further decrease was observed after intra-
venous injection of Manning compound (from 119  2
to 72  5 mmHg; P  0.05). No changes in HR were
Fig. 5. Effects of bilateral microinjection of
100 pmol/100 nl (A) and 1,000 pmol/100 nl (B)
baclofen into the NTS, followed by intrave-
nous injection of prazosin (1 mg/kg) and va-
sopressin antagonist (Manning compound, 10
g/kg) on PAP, MAP, and HR. Time between
treatments was 15 min.
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observed after prazosin and Manning compound treat-
ments (Fig. 4B). Figure 3B shows a representative
tracing from an animal of this group.
In a control experiment, VP antagonist injection
after bilateral microinjection of saline into the NTS did
not cause significant changes in MAP (basal 116  4
mmHg, after saline 116 4 mmHg, and after Manning
compound 114  4 mmHg; P 
 0.05).
MAP and HR effects of sequential systemic adminis-
tration of Manning compound and prazosin after bilat-
eral microinjection of baclofen into NTS of conscious
rats. Bilateral microinjection of baclofen (100 pmol/100
nl) increased MAP from 111 3 to 163 7 mmHg (n
6; P  0.05); however, HR did not change (358  10 vs.
373  13 beats/min; see Fig. 6A). Fifteen minutes after
baclofen microinjection, rats received Manning com-
pound (10 g/kg iv), which lowered MAP from 163  7
to 148  6 mmHg (P  0.05). Fifteen minutes after
Manning compound treatment, prazosin (1 mg/kg iv)
decreased MAP from 148  6 to 68  1 mmHg and
elicited a significant increase in HR from 375  13 to
468  10 beats/min (n  6, P  0.05; see Fig. 6A).
Figure 5A shows a representative tracing from an
animal of this group.
The same protocol was repeated on a group of six
rats that received bilateral microinjection of 1,000
pmol/100 nl of baclofen in the NTS. Baclofen microin-
jection increased MAP from 114  6 to 185  6 mmHg
and HR from 335  9 to 458  9 beats/min (P  0.05).
The following intravenous administration of Manning
compound decreased MAP from 185  6 to 168  5
mmHg (P  0.05), and the consecutive administration
of prazosin decreased MAP from 168  5 to 58  7
mmHg (P 0.05). HR remained at the same level after
the first treatment (baclofen). Tachycardia was absent
in this group, which showed a much greater fall in
MAP (from 168 5 to 58 7 mmHg, P 0.05; Fig. 6B).
Figure 5B shows a representative tracing from an
animal of this group.
DISCUSSION
The present study shows that the GABAB receptor
agonist baclofen microinjected into the NTS increases
arterial pressure in conscious rats. Other studies (14,
15) showed that GABA microinjections into the NTS
increase blood pressure in anesthetized rats. These
studies also reported that microinjections of the
GABAA antagonist bicuculine produce hypotension in
anesthetized rats (14, 15).
Bilateral microinjection of muscimol (GABAA ago-
nist) (7), or electrolytic and chemical lesions (1) or
bilateral microinjections of baclofen into the NTS (9),
elicits tachycardia in anesthetized animals. Our study
demonstrated that a GABAB-selective agonist also elic-
its a pressor response in conscious rats. Only animals
that received microinjections of baclofen at the highest
dose (1,000 pmol/100 nl) displayed tachycardia,
whereas the other doses did not demonstrate consis-
tent changes in HR. An exception was that, in the
second protocol, 100 pmol/100 nl baclofen produced a
significant tachycardia. This result could be due to the
highest variance observed in HR basal level. We would
expect that such an effect could result from baroreflex
Fig. 6. Effects of bilateral microinjec-
tion of 100 pmol/100 nl (A; n  6) and
1,000 pmol/100 nl (B; n  6) baclofen
into the NTS and intravenous injection
of prazosin (1 mg/kg) and vasopressin
antagonist (Manning compound, 10 g/
kg) on MAP and HR. *Different com-
pared with control (P  0.05); †differ-
ent from baclofen (P 0.05); #different
from baclofen  prazosin (P  0.05).
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inhibition in addition to an increased sympathetic to-
nus elicited by baclofen. The fact that the prazosin-
induced fall in blood pressure in rats pretreated with
the highest dose of baclofen was not accompanied by
tachycardia suggests that impairment of baroreflex
activity may be involved in these differences in HR
responses.
The dose-related increase in MAP after bilateral
microinjection of baclofen into the NTS indicates that
the inhibition of this system by microinjection of ba-
clofen results in a pressor response. One of the mech-
anisms that produce the pressure response is the re-
lease of VP (7, 13). Studies in anesthetized rats (7)
demonstrated an increase in plasma VP during the
increase of arterial pressure elicited by microinjection
of muscimol into the NTS. This hypertension elicited
by muscimol was reversed by intravenous injection of a
vasopressin antagonist (7). Chemical or electrolytic
lesions of the NTS produce hypertension that cannot be
abolished solely by vasopressin antagonists but can be
abolished by lesions or application of glycine into the
rostroventrolateral medulla, suggesting that bilateral
lesions of the NTS increased sympathetic tonus and
also the release of vasopressin (1). In the ongoing
study, baclofen-induced hypertension was reversed by
peripheral blockade of 1-adrenoreceptors and addi-
tional systemic administration of a vasopressin antag-
onist further lowered MAP below control levels.
To test the hypothesis that both the release of VP
and an increase in sympathetic tonus occur simulta-
neously when baclofen is microinjected into the NTS
rather than the administration of prazosin lowering
AP and stimulating VP release, a group of animals
received an intravenous injection of VP antagonist
first. This produced a significant but small decrease in
the baclofen-induced hypertension. The remaining hy-
pertension was then completely reversed by intrave-
nous injection of prazosin. Besides demonstrating an
involvement of VP in baclofen-induced hypertension,
these data suggest that baclofen-induced hypertension
is more dependent on sympathetic tonus activation.
The possible mechanisms for mediation of the hyper-
tension elicited by baclofen within the NTS are not
completely understood; however, there is evidence that
GABAB receptors within the NTS modulate arterial
baroreflexes (5, 27, 30). A recent study (33) suggested a
presynaptic mechanism contributing to the inhibition
of aortic depressor nerve inputs by GABAB receptors
within the NTS. This same study also observed that
monosynaptic neurons in the NTS were less sensitive
to GABAB-mediated inhibition than polysynaptic neu-
rons (33). However, the aortic depressor nerve-evoked
discharge of some NTS neurons was insensitive to
baclofen, suggesting the existence of subpopulations of
monosynaptic neurons with differing sensitivities to
GABAB inhibition (33). In our present findings, we
observed dose-dependent pressor responses to microin-
jection of baclofen. Doses of 100 pmol/100 nl elicited a
pressor response without HR changes. In a subsequent
protocol, peripheral blockade of 1-adrenoreceptors vir-
tually eliminated baclofen (100 pmol/100 nl) induced
hypertension and resulted in a possible reflex tachy-
cardia (see Fig. 3). Alternatively, dose-dependent ef-
fects of baclofen have been described in in vitro studies
of NTS (5). Low doses of baclofen produced presynaptic
inhibitory effects, whereas higher doses produced a
mixture of pre- and postsynaptic inhibition. In this
model, we might speculate that, with a higher dose of
baclofen, we would observe enhanced hypertension and
significant tachycardia. Treatment in those animals
with prazosin and VP receptor antagonist completely
reversed hypertension and resulted in no change in
HR. Considering that we are using microinjections, we
may speculate that different doses of baclofen could be
altering the activity of different subpopulations of neu-
rons in the NTS.
These data indicate the involvement of the two sys-
tems studied after the inhibition of the NTS by bilat-
eral microinjections of baclofen in conscious rats: 1) the
SNS and 2) the release of VP. According to our results,
the main system responsible for the hypertension that
followed NTS inhibition is the SNS once systemic ad-
ministration of prazosin was able to completely reverse
the hypertension.
In conclusion, our results show that the hyperten-
sion induced by baclofen microinjected into the NTS of
conscious rats was produced by increases in sympa-
thetic tonus and may involve the release of VP. These
data suggest that NTS neurons exert a tonic inhibitory
influence on the SNS and possible mechanisms related
to VP release.
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